These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. New advances in the treatment of hematologic malignancies: focus on topoisomerase I inhibitors. Introduction. Kantarjian H Semin Hematol; 1998 Jul; 35(3 Suppl 4):1-2. PubMed ID: 9779875 [No Abstract] [Full Text] [Related]
5. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance]. Pourquier P; Pommier Y Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078 [TBL] [Abstract][Full Text] [Related]
6. Recent developments in the clinical activity of topoisomerase-1 inhibitors. Kreditor M; Fink M; Hochster HS Cancer Chemother Biol Response Modif; 2005; 22():61-100. PubMed ID: 16110608 [No Abstract] [Full Text] [Related]
7. Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia. Beran M Leuk Res; 2004 May; 28(5):443-6. PubMed ID: 15068895 [No Abstract] [Full Text] [Related]
9. Antitumour drug design: DNA-binding ligands, which inhibit the topoisomerase I. Pindur U; Lemster T Pharmazie; 1998 Feb; 53(2):79-86. PubMed ID: 9540103 [TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification. You QD; Li ZY; Huang CH; Yang Q; Wang XJ; Guo QL; Chen XG; He XG; Li TK; Chern JW J Med Chem; 2009 Sep; 52(18):5649-61. PubMed ID: 19715319 [TBL] [Abstract][Full Text] [Related]
11. The use of topoisomerase I inhibitors in multiple myeloma. Kraut EH; Ju R; Muller M Semin Hematol; 1998 Jul; 35(3 Suppl 4):32-8. PubMed ID: 9779880 [TBL] [Abstract][Full Text] [Related]
12. DNA topoisomerase expression in tumors--a novel target for chemotherapy. Rubin EH Hum Pathol; 2000 Jun; 31(6):631-2. PubMed ID: 10872653 [No Abstract] [Full Text] [Related]
13. Novel camptothecin derivatives as topoisomerase I inhibitors. Basili S; Moro S Expert Opin Ther Pat; 2009 May; 19(5):555-74. PubMed ID: 19441934 [TBL] [Abstract][Full Text] [Related]
14. DNA topoisomerase i as a transcription protein and a lethal cellular toxin. Lotito L; Ferri F; Russo A; Capranico G Ital J Biochem; 2007 Jun; 56(2):122-9. PubMed ID: 17722653 [TBL] [Abstract][Full Text] [Related]
15. Infusional chemotherapy with new drugs: taxanes, vinorelbine and topoisomerase I inhibitors. Dieras V; Pouillart P J Infus Chemother; 1995; 5(4):191-2. PubMed ID: 8934724 [No Abstract] [Full Text] [Related]
16. Topoisomerase I interactive agents. Kirstein MN; Turner PK; Stewart CF Cancer Chemother Biol Response Modif; 2002; 20():99-123. PubMed ID: 12703202 [TBL] [Abstract][Full Text] [Related]
17. Emerging DNA topisomerase inhibitors as anticancer drugs. Denny WA Expert Opin Emerg Drugs; 2004 May; 9(1):105-33. PubMed ID: 15155139 [TBL] [Abstract][Full Text] [Related]
18. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities. Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102 [TBL] [Abstract][Full Text] [Related]
19. Synthesis of 2,6-diaryl-substituted pyridines and their antitumor activities. Son JK; Zhao LX; Basnet A; Thapa P; Karki R; Na Y; Jahng Y; Jeong TC; Jeong BS; Lee CS; Lee ES Eur J Med Chem; 2008 Apr; 43(4):675-82. PubMed ID: 17673337 [TBL] [Abstract][Full Text] [Related]
20. Terbenzimidazoles: influence of 2"-, 4-, and 5-substituents on cytotoxicity and relative potency as topoisomerase I poisons. Kim JS; Yu C; Liu A; Liu LF; LaVoie EJ J Med Chem; 1997 Aug; 40(18):2818-24. PubMed ID: 9288163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]